Ennovation Ventures

Company Profile

We focus on life science, health care, original innovation

Enran Ventures was established in 2015, focusing on venture capital companies in the fields of biomedicine and medical health. It currently manages eight equity investment funds with a management scale of more than 3 billion...

300000Million

Managed amount

65Companies

Invested companies

7Sticks

Number of funds

management team

View all team members>>

Mr. Renhai Chen

Mr. Renhai Chen

Ms. Yijia Zhang

Ms. Yijia Zhang

Mr. Jintao Deng

Mr. Jintao Deng

Mr. Yilang Cheng

Mr. Yilang Cheng

Portfolio

Ennovation Ventures Portfolio | Immunophage and Shanghai Gaobo Cancer Hospital Affiliated to China Pharmaceutical University Reach a Comprehensive Strategic Cooperation on the Phase II Clinical Trial of the Globally Innovative Drug IPG7236

Recently, ImmunophagePharmaceuticals announced that it has reached a comprehensive strategic cooperation with Shanghai

Ennovation Ventures Portfolio | The First in China | Freeze-dried RSV mRNA Vaccine Approved for Clinical Trial

On December 24, 2024, the freeze-dried mRNA respiratory syncytial virus (RSV) vaccine NR2222 independently developed

Ennovation Ventures Portfolio | A Must for 190 Million Patients Globally! Hope Medicine's New Drug for Endometriosis Hits the Pain Points, with Positive Progress in Phase 2

Endometriosis is a common gynecological disease characterized by the implantation of endometrial cells outside the

Ennovation Ventures Portfolio | Hope Medicine Inc.'s Monoclonal Antibody HMI-115 Obtains the Designation of Breakthrough Therapy by CDE

Recently, Hope Medicine Inc (Hope Medicine hereinafter) announced that its new class 1 monoclonal antibody drug H

Ennovation Ventures Portfolio | InxMed Linited's Ifebemtinib: Included in the Breakthrough Therapy Category for First-line Treatment of Non-small Cell Lung Cancer; Improving the Therapeutic Window of ADC Drugs

Ifebemtinib (IN10018, BI853520) is a small molecule inhibitor targeting focal adhesion kinase (FAK) developed byInxM

Ennovation Ventures Portfolio | LeadsBiolabs and Aditum Bio Collaborate to Establish Oblenio Bio, Fully Promoting the R&D of Tri-specific T Cell Engagers in the Autoimmune Field

Nanjing, China, Oakland, USA - On November 7, 2024, Nanjing LeadsBiolabs Co , Ltd (hereinafter referred to as "L

Ennovation Ventures Portfolio | Innovation Healthcare (SZ: 002173) Makes a Strategic Investment in Quanzhen Medicine

Overview of This TransactionInnovation Healthcare Management Co , Ltd (hereinafter referred to as the "Company") jo

Ennovation Ventures Portfolio | BenDao Gene and Shanghai Pharmaceutical Ruier Reach a Next-Generation Lentiviral Vector Technology Cooperation

On August 6, 2024, Shanghai Pharmaceutical Ruier Pharmaceutical Co , Ltd (referred to as "Shanghai Pharmaceutical

Ennovation Ventures Portfolio丨Dr. Xue Chong from QuanZhenTong Showcases the Application of "QuanZhen AI" Medical Large Model at the 2024 World Artificial Intelligence Conference

From July 4th to July 6th, 2024, the 2024 World Artificial Intelligence Conference and the High-level Conference

Ennovation Ventures Portfolio丨Focusing on differentiated innovation, Leads Biolabs was selected for the 2023 Hurun Global Cheetah Enterprise List

On December 19th, Hurun Research Institute and Guangzhou Nansha jointly released the "2023 Hurun Global Cheetah En